Zyclara (Imiquimod) Patent Expiration, LOE Window & CMS Spending

Zyclara (Imiquimod) by Bausch Health: FDA Orange Book LOE 2030-04-30, 5 AB generics, $214K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN022483 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-04-30
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$214K
2024 Medicare Part D Spend$104K
2024 Medicaid Spend$110K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.